Shots:

• Astellas to acquire Audentes in all-cash transactions at $6/share making a total deal value as $3B with a premium of 110% to Audentes’ closing share price of US$28.61 on December 2- 2019. The Transaction is expected to be completed in Q1’20
• The focus of the collaboration is to robust Astellas’ rare neuromuscular diseases pipeline by combining Astellas’ capabilities and global resources with Audentes’ AAV gene therapy technology platform and allow Astellas to access Audentes’ leading program- AT132 for X-Linked Myotubular Myopathy (XLMTM)
• The collaboration will lead to the expansion of the Astellas Focus Area approach by adding fifth Primary Focus Area in Genetic Regulation and provide an opportunity to Astellas for additional gene therapy partnerships and pipeline expansion by leveraging Audentes’ manufacturing capabilities

Click here to­ read full press release/ article | Ref: Buisnesswire | Image:  PRNewswire